Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
Jenseits der G-CSF-Mobilisierung – 15 Jahre Erfahrung mit verschiedenen Stammzellmobilisationsschemata beim Multiplen Myelom
Cancer Medicine · 2025-07 · 14 (14)
DOI: 10.1002/cam4.71068 ↗Auf einen Blick
Bei 200 Patient:innen mit Multiplem Myelom wurden vier Mobilisationsregime verglichen. Cyclophosphamid-basierte Schemata erzielten höhere Gesamt-Ausbeuten; die Einmalapherese war ähnlich wie bei G-CSF + Plerixafor.
Fragestellung
Welche Mobilisationsregime erreichen beim Multiplen Myelom die beste CD34+-Ausbeute in der ersten Apherese und insgesamt?
Methode
Retrospektive Analyse über 15 Jahre; 200 Patient:innen, 205 Mobilisierungsversuche, September 2007 bis Dezember 2022; Vergleich von 4 Mobilisationsregimen.
Ergebnisse
CD34+ ≥ 5 × 10^6/kg in der ersten Apherese: 26 %, 53 %, 69 %, 63 % in Gruppe 1–4 (p = 0,0001). Medianer Ertrag erste Apherese: 3,62; 5,20; 6,04; 6,05. Gesamt: 5,73; 6,17; 9,14; 8,23 (p < 0,00001).
Schlussfolgerung der Autor:innen
Cyclophosphamid-basierte Chemo-Mobilisierung mit oder ohne Bortezomib hatte Vorteile beim Gesamtertrag; für die Gewinnung in einer einzelnen Apherese war sie G-CSF + Plerixafor gleichwertig. Bortezomib zu Cyclophosphamid kann den Ertrag erhöhen.
Kernaussagen
- Vier Mobilisationsregime bei Multiplem Myelom verglichen
- Höchster Gesamt-Ertrag unter Bortezomib + Cy-G-CSF
- Einmalapherese ähnlich zu G-CSF + Plerixafor
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.07.2025. Verfasst von Sumeet Mirgh und 18 weiteren Autor:innen. Beteiligte Einrichtung: BMT Unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Mobilization, Granulocyte Colony-Stimulating Factor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Background
Stem‐cell mobilization in multiple myeloma is usually done with G‐CSF with or without Cyclophosphamide (Cy) based chemotherapy/Plerixafor. Pre‐clinical data suggest the role of proteasome inhibitors in mobilization. We previously reported that Bortezomib (Bort) when added to a Cy‐based regimen had a better stem‐cell yield. Consequent to favorable results with Bort + Cy‐G‐CSF, we used Bortezomib with G‐CSF too. Hence, four different mobilization regimens were used—Bort + G‐CSF (Group‐1); G‐CSF + Plerixafor (Group‐2); Bort – Cy‐G‐CSF (Group‐3); Cy + G‐CSF (Group‐4). We report here our 15‐year retrospective analysis of these 4 mobilization regimens.
Objectives
Primary objective was to determine proportion of patients with CD34 + dose ≥ 5 × 10 6 /kg in first apheresis in various groups. Secondary objectives were to determine median CD34 + dose (×10 6 /kg) in first apheresis, total median CD34 + dose (×10 6 /kg) of all harvests and frequency of mobilization failure. Mobilization failure was defined as total CD34 + dose of < 2 × 10 6 /kg or abandoned harvest attempt at physician's discretion after anticipating a poor collection.
Results
All consecutive patients with MM aged 18–65 years who underwent stem‐cell mobilization from September 2007–December 2022 were included. In an intention‐to‐treat analysis, a total 200 patients with 205 mobilization attempts were analysed. The median age of the cohort was 48 years. The percentage of patients who collected ≥ 5 × 10 6 CD34 + cells/kg in the first apheresis was 26%, 53%, 69%, and 63% in Groups 1–4, respectively ( p = 0.0001). The median CD34 yield in the first harvest (×10 6 /kg) was 3.62, 5.20, 6.04, and 6.05 in Groups 1–4, respectively ( p = 0.00004). The median total stem‐cell dose collected (×10 6 /kg) was 5.73, 6.17, 9.14, and 8.23 in Groups 1–4, respectively ( p < 0.00001). Mobilization failure rates were 7%, 3%, 0%, and 2%, respectively ( p = NS).
Conclusion
Cyclophosphamide‐based chemo‐mobilization regimens with or without Bortezomib have the advantage of higher total stem‐cell yield, while they are equivalent to G‐CSF + Plerixafor for harvest in a single apheresis. The addition of Bortezomib to Cyclophosphamide may help to increase stem cell yield.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BMT Unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Navi Mumbai, India.
- Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Transfusion Medicine, Tata Memorial Centre, ACTREC, Navi Mumbai, India.
- Department of Hematopathology, Tata Memorial Centre, ACTREC, Navi Mumbai, India.
ORCID-Profile: Sumeet Mirgh, Navin Khattry
Zitieren
APA
Mirgh, S., Bagal, B., Punatar, S., Gokarn, A., Jindal, N., Chichra, A., Nayak, L., Hiregoudar, S., Poojary, M., Saha, S., Parab, S., Ojha, S., Tembhare, P., Patkar, N., Rajpal, S., Chatterjee, G., Mathew, L., Subramanian, P., & Khattry, N. (2025). Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma. Cancer Medicine, 14(14). https://doi.org/10.1002/cam4.71068
Vancouver
Mirgh S, Bagal B, Punatar S, Gokarn A, Jindal N, Chichra A, et al. Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma. Cancer Medicine. 2025;14(14). doi:10.1002/cam4.71068
BibTeX
@article{Mirgh2025,
author = {Mirgh, Sumeet and Bagal, Bhausaheb and Punatar, Sachin and Gokarn, Anant and Jindal, Nishant and Chichra, Akanksha and Nayak, Lingaraj and Hiregoudar, Sumathi and Poojary, Minal and Saha, Suryatapa and Parab, Sarika and Ojha, Shashank and Tembhare, Prashant and Patkar, Nikhil and Rajpal, Sweta and Chatterjee, Gaurav and Mathew, Libin and Subramanian, Papagudi and Khattry, Navin},
title = {Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {14},
doi = {10.1002/cam4.71068}
}
EUVIMED